Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
News|Articles|March 2, 2026
FDA updates in urology: February 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
A recap of the FDA submissions and regulatory decisions in urology from February 2026.
Advertisement
Advertisement
Welcome to Urology Times’® monthly FDA update! February’s regulatory news was characterized by updates in the men’s and women’s health space, in addition to a notable milestone in the development of an investigational agent for urothelial carcinoma. At the end of February, the field also saw 2 FDA submissions for belzutifan-based combinations in kidney cancer based on data presented at the 2026
Related to this article
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
The PDUFA target action date is in the fourth quarter of 2026.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and pCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement